focus -WSS

focus

author：entertainment 2025-09-30 01:14:15 - browse：6

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

WSS

Woodcock on FDA’s accelerated approval and her next chapter

Man who had jail sentence commuted by Trump arrested again

India sets sights on home

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Some dementia cases could be undiagnosed liver disease

explore

focus

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

Couple fighting to bring baby home from Mexico are finally reunited

Novavax promises a turnaround & Lilly roils the obesity market

ARCH Venture Partners is raising $3 billion for a life sciences fund

Hepatitis C has a cure — but many Americans still lack access to it

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Wildfire smoke exposes gaps in outdoor worker protections

Couple fighting to bring baby home from Mexico are finally reunited

Trump demands the U.S. pay no more for drugs than other countries … again

Trump got a 'target letter.' What is one and what does it mean?

focus

Vertex non

Novo Nordisk to expand supply of Wegovy for U.S. patients

Researchers separate signal from noise in heart wearable data

Apple Vision Pro: A first look at health apps on the new VR headset

SAMSHA loosens regulations on methadone treatment centers

Quicker fix for pulse oximeters urged during FDA public meeting

entertainment

Wikipedia

entertainment

hotspot